MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- AJANTA PHARMA
AJANTA PHARMA Share Price 
(AJPH)
Here is the latest stock price and chart of AJANTA PHARMA. For more details, see the AJANTA PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jun 24, 2019 02:17:00 PM | ||
|---|---|---|---|
| Price (Rs)960.80 | Open (Rs) 953.25 | High (Rs) 963.60 | Low (Rs) 934.50 |
| % Change0.64 | Volume 11,651 | Value (Rs) 11,194,281 | 52-Week H/L 1,294.10 / 903.10 |
| Live NSE Quotes | Jun 24, 2019 2:19:56 PM | ||
|---|---|---|---|
| Price (Rs)961.15 | Open (Rs) 953.00 | High (Rs) 963.10 | Low (Rs) 933.00 |
| % Change0.69 | Volume 225,819 | Value (Rs) 213,717,360 | 52-Week H/L 1,294.00 / 900.10 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 44.00 | P/E Ratio (x) 21.84 | Market Cap (Rs m) 84,502.36 | P/BV (x) 3.76 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
AJANTA PHARMA Share Price Today:
AJANTA PHARMA share price is up 0.6% to Rs 960.8 on the BSE. On the NSE, the AJANTA PHARMA share price is up 0.7% to Rs 961.2. The total volume of shares traded is 0.2 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 0.1%. And the benchmark S&P BSE SENSEX is at 39,118.7 (down 0.2%).
Over the last 30 days, the AJANTA PHARMA share price is down 5.3%. And over the last one year, AJANTA PHARMA share price is down 7.9%.
|
| |
Today's Market
Indian Indices Trade on a Flat Note; Oil & Gas and Automobile Stocks Drag(12:30 pm)
Share markets in India are presently trading on a flat note. Sectoral indices are trading mixed with stocks in the oil & gas sector, automobile sector.
Related Views On News
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)
May 3, 2019 | Updated on May 3, 2019For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)
Feb 1, 2019 | Updated on Feb 1, 2019For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)
Jun 12, 2019This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
7 Bluechips to Profit from Tech Disruption(Profit Hunter)
Jun 17, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
MoreTRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA - ADCOCK INGRAM COMPARISON
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.